share_log

As GuangYuYuan Chinese Herbal Medicine (SHSE:600771) Ascends 4.8% This Past Week, Investors May Now Be Noticing the Company's Three-year Earnings Growth

As GuangYuYuan Chinese Herbal Medicine (SHSE:600771) Ascends 4.8% This Past Week, Investors May Now Be Noticing the Company's Three-year Earnings Growth

隨着廣譽遠中藥(SHSE:600771)上週上漲4.8%,投資者現在可能會注意到該公司過去三年的收益增長。
Simply Wall St ·  07/22 19:05

Investing in stocks inevitably means buying into some companies that perform poorly. Long term GuangYuYuan Chinese Herbal Medicine Co., Ltd. (SHSE:600771) shareholders know that all too well, since the share price is down considerably over three years. So they might be feeling emotional about the 61% share price collapse, in that time. And the ride hasn't got any smoother in recent times over the last year, with the price 40% lower in that time. Shareholders have had an even rougher run lately, with the share price down 22% in the last 90 days.

投資於股票不可避免地意味着購買一些表現不佳的公司。長揸廣譽遠中藥股份有限公司(SHSE: 600771)的股東深有體會,因爲股價在三年內大幅下跌。因此,在那段時間裏,他們可能會感到情緒低落,因爲股價下跌了61%。而在過去一年中,情況並沒有變得更順暢,股價在那段時間內下跌了40%。股東們最近的情況更加糟糕,股價在過去90天下跌了22%。

While the stock has risen 4.8% in the past week but long term shareholders are still in the red, let's see what the fundamentals can tell us.

雖然該股上週上漲了4.8%,但長期股東仍未獲得收益,讓我們看看基本面能爲我們提供什麼信息。

While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS).

雖然有效市場假說仍然被一些人教授,但被證明市場是過度反應的動態系統,投資者並不總是理性的。檢查市場情緒如何隨時間變化的一種方法是看一個公司的股價與其每股收益(EPS)之間的交互作用。

GuangYuYuan Chinese Herbal Medicine became profitable within the last five years. That would generally be considered a positive, so we are surprised to see the share price is down. So given the share price is down it's worth checking some other metrics too.

廣譽遠中藥股份有限公司在過去五年內實現了盈利。這通常被認爲是積極的,因此我們對股價下跌感到驚訝。所以,鑑於股價下跌,值得檢查一些其他的指標。

We note that, in three years, revenue has actually grown at a 11% annual rate, so that doesn't seem to be a reason to sell shares. This analysis is just perfunctory, but it might be worth researching GuangYuYuan Chinese Herbal Medicine more closely, as sometimes stocks fall unfairly. This could present an opportunity.

我們注意到,營業收入在三年內實際上以11%的年度增長率增長,因此這似乎不是出售股票的原因。這種分析只是例行公事,但值得更仔細地研究廣譽遠中藥股份有限公司,因爲有時股票可能會不公平地下跌。這可能會產生機會。

The image below shows how earnings and revenue have tracked over time (if you click on the image you can see greater detail).

下圖顯示了收益和營收隨時間變化的情況(如果你點擊圖像,可以看到更多細節):

big
SHSE:600771 Earnings and Revenue Growth July 22nd 2024
SHSE:600771收益和營收增長2024年7月22日

You can see how its balance sheet has strengthened (or weakened) over time in this free interactive graphic.

你可以在這個免費的互動圖表中看到它的資產負債表如何隨着時間的推移而加強(或削弱)。

A Different Perspective

不同的觀點

While the broader market lost about 15% in the twelve months, GuangYuYuan Chinese Herbal Medicine shareholders did even worse, losing 40%. Having said that, it's inevitable that some stocks will be oversold in a falling market. The key is to keep your eyes on the fundamental developments. On the bright side, long term shareholders have made money, with a gain of 0.8% per year over half a decade. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Even so, be aware that GuangYuYuan Chinese Herbal Medicine is showing 1 warning sign in our investment analysis , you should know about...

儘管整個股市在十二個月內下跌了約15%,而廣譽遠中藥股份有限公司的股東表現得更糟,損失了40%。話雖如此,在一個下跌的市場中,某些股票被超賣是不可避免的。關鍵是關注基本面的發展。從好的方面來看,長期股東已經賺到了錢,過去半個十年的年均收益率爲0.8%。如果基本數據繼續表明長期可持續增長,當前的拋售可能值得考慮。我發現看長期的股價表現作爲業務表現的一種代理十分有趣。但是爲了真正獲得見解,我們需要考慮其他信息。即使如此,請注意,廣譽遠中藥股份有限公司在我們的投資分析中顯示出一個警告標誌,您應該了解。

If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: many of them are unnoticed AND have attractive valuation).

如果您喜歡與管理層一起購買股票,那麼您可能會喜歡這個公司的免費列表。 (提示:其中許多公司不爲人注意且具有吸引力的估值。)

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.

請注意,本文引用的市場回報反映了目前在中國交易所上市的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論